Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2015

View Archived Issues

Shire reports pipeline highlights of fourth quarter 2014

Zydus completes phase I studies of ZYAN-1

Impaired mTORC1 activity linked to phenotypic changes associated with Huntington's disease

Saniona regains rights to GABA-alpha5 program

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2014

VistaGen and NIH sign agreement for phase II AV-101 trial in major depressive disorder

FDA grants fast track designation to intranasal naloxone treatment

FDA gives orphan drug status to entrectinib for colorectal cancer

Nanjing Sanhome Pharmaceutical patents ABL inhibitors

Phase II trial of MRX-6 in pediatric atopic dermatitis does not reach primary endpoint

Alethia Biotherapeutics submits clinical trial application for AB-16B5

PBI-4050 granted U.S. orphan drug status for IPF

VBL Therapeutics reports data from VB-201 trials in psoriasis and ulcerative colitis

Roche develops neurogenesis-stimulating naphthyridines

Zenith Epigenetics reports novel bromodomain inhibitors

Nattokinase shows efficacy for ischemic brain damage

Novartis patent divulges PI3Kdelta/gamma inhibitors

Intrexon to acquire recombinant bacterial therapeutics developer ActoGeniX

Takeda Pharmaceutical patents new PDE2A inhibitors

ADAMTS13, a potential biomarker of response to thrombolysis in acute stroke

Alzheimer's Research U.K. funds three drug discovery institutes

Sprout Pharmaceuticals resubmits NDA for flibanserin in HSDD

Elite Pharmaceuticals plans phase III trial of abuse-deterrent opioid

SB-623 cell therapy shows encouraging results for chronic stroke

Pluristem Therapeutics reports results for PLX-R18 in animal model of ARS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...